Evidence map›Paper›PMID 26772905›Full record

ArticleContraception2016

Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity.

Jenell S Coleman, Edward Fuchs, Wutyi S Aung, Mark A Marzinke, Rahul P Bakshi, Hans M L Spiegel, Jennifer Robinson, Craig W Hendrix

Open access · greenAbstract read
In one paragraph

Article in Contraception, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jenell S ColemanJohns Hopkins University School of Medicine, Department of Gynecology & Obstetrics; Johns Hopkins University School of Medicine Division of Clinical Pharmacology, Department of Medicine. Electronic address: colemanj@jhmi.edu.
Edward FuchsJohns Hopkins University School of Medicine Division of Clinical Pharmacology, Department of Medicine.
Wutyi S AungJohns Hopkins University School of Medicine Division of Clinical Pharmacology, Department of Medicine.
Mark A MarzinkeJohns Hopkins University School of Medicine Division of Clinical Pharmacology, Department of Medicine; Johns Hopkins University School of Medicine, Department of Pathology.
Rahul P BakshiJohns Hopkins University School of Medicine Division of Clinical Pharmacology, Department of Medicine.
Hans M L SpiegelHJF-DAIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.
Jennifer RobinsonJohns Hopkins University School of Medicine, Department of Gynecology & Obstetrics; Johns Hopkins University School of Medicine Division of Clinical Pharmacology, Department of Medicine.
Craig W HendrixJohns Hopkins University School of Medicine Division of Clinical Pharmacology, Department of Medicine.
Johns Hopkins University · USJohns Hopkins Medicine · USNational Institute of Allergy and Infectious Diseases · US

Funding

Pharmaceutical and Regulatory CoreU19AI082639 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2010 to 2014
$13.0M
Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PKR01AI110371 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COLEMAN, JENELL S, HENDRIX, CRAIG WALTER · 2013 to 2017
$2.2M
NIAID NIH HHS HHSN272200800014CNIAID NIH HHS R01 AI110371NIAID NIH HHS U19 AI082639NIAID NIH HHS U19 AI0882639NIGMS NIH HHS T32 GM066691PHS HHS HHSN272200800014C
6 · The paper itself

Abstract

objectiveTo determine the feasibility of using quantitative changes in vaginal permeability to small molecules as a measure of candidate microbicide toxicity. STUDY

designControlled, open-labeled, prospective study. Seven healthy women received a single vaginal dose of hydroxyethylcellulose gel (HEC), nonoxynol-9 (N-9) or K-Y Jelly. Each gel was radiolabeled with a small molecule ((99m)Tc-DTPA) followed by 12-h blood and urine collection. Pharmacokinetic (PK) parameters of (99m)Tc-DTPA were calculated to compare the impact of each gel on vaginal permeability. Each woman served as her own control. The Friedman test with post hoc Wilcoxon test was used to detect differences among the gels.

resultsVaginal permeability of (99m)Tc-DTPA was highest for the N-9 radiolabel. N-9 plasma area under the concentration curve was 2.7-fold higher (p=.04), and peak concentration was threefold higher (p=.04) compared to HEC. There were no significant PK parameter differences between HEC and K-Y Jelly or between N-9 and K-Y Jelly. Cumulative dose-adjusted median (interquartile range) 12-h timed urine gamma activity was 66.70 × 10(-4)μCi (27.90-152.00) following HEC dosing, 103.00 × 10(-4)μCi (98.20-684.00) following N-9 gel dosing and 20.30 × 10(-4)μCi (11.10-55.90) following K-Y gel dosing. The differences between urine HEC and K-Y Jelly (p=.047) and between N-9 and K-Y Jelly (p=.016) were statistically significant.

conclusionsIt is feasible to measure differences in vaginal permeability among vaginal gels using a radiolabeled small molecule, though there are permeability differences that require a nuanced understanding of gel composition to interpret the results. IMPLICATIONS: Establishing the safety of both vehicle and active pharmaceutical ingredient is an essential task in microbicide development, to be determined as soon as possible. This study suggests that a combination of microbicide toxicity assessments, that is, cervicovaginal permeability, inspection and histopathology, may need to be studied simultaneously.

Indexed as

Cell Membrane PermeabilityAdolescentAdultAnti-Infective AgentsCelluloseFemaleGelsGlycerolHIV InfectionsHumansMiddle AgedNonoxynolPhosphatesPropylene GlycolsProspective StudiesTechnetium Tc 99m PentetateAnti-Infective AgentsCelluloseGelsGlycerolhydroxyethylcelluloseK-Y jellyNonoxynolPhosphatesPropylene GlycolsTechnetium Tc 99m PentetateVaginal Creams, Foams, and JelliesHIVMicrobicideN-9PermeabilitySpermicide

Identifiers

PMID26772905
PMCPMC4783221
OpenAlexW2226785108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.